Summary
DexCom, Inc. reported strong financial performance for the first quarter of 2020, with revenues reaching $405.1 million, a significant 44% increase compared to $280.5 million in the same period of 2019. This growth was primarily driven by increased sales volume of disposable sensors. The company also demonstrated improved profitability, with gross profit increasing by 52% to $256.5 million and operating income turning positive at $33.6 million, a substantial improvement from an operating loss of $14.4 million in the prior year's first quarter. Net income for the quarter was $19.9 million, a marked turnaround from a net loss of $26.9 million in Q1 2019. Despite the positive financial results, the company acknowledged the potential impacts of the COVID-19 pandemic, noting that the extent of future impacts remains uncertain. DexCom highlighted its continued investment in research and development and selling, general, and administrative expenses to support future growth. The company's liquidity position remains strong, with $1,510.5 million in cash, cash equivalents, and short-term marketable securities as of March 31, 2020.
Financial Highlights
49 data points| Revenue | $405.10M |
| Cost of Revenue | $148.60M |
| Gross Profit | $256.50M |
| R&D Expenses | $73.10M |
| SG&A Expenses | $149.80M |
| Operating Expenses | $222.90M |
| Operating Income | $33.60M |
| Interest Expense | $15.40M |
| Net Income | $19.90M |
| EPS (Basic) | $0.06 |
| EPS (Diluted) | $0.05 |
| Shares Outstanding (Basic) | 367.20M |
| Shares Outstanding (Diluted) | 376.40M |
Key Highlights
- 1Revenue increased by a robust 44% year-over-year to $405.1 million, driven by higher sales volumes, particularly of disposable sensors.
- 2Gross profit surged 52% to $256.5 million, with gross margin improving to 63% from 60% in the prior year, attributed to increased revenues and product cost reductions.
- 3The company returned to profitability, reporting a net income of $19.9 million in Q1 2020, a significant improvement from a net loss of $26.9 million in Q1 2019.
- 4Operating income turned positive at $33.6 million, a substantial recovery from an operating loss of $14.4 million in the prior year's first quarter.
- 5Research and development expenses increased by 24% to $73.1 million, reflecting continued investment in innovation.
- 6Selling, general, and administrative expenses rose 21% to $149.8 million, supporting commercialization efforts and growth.
- 7DexCom maintained a strong liquidity position with $1,510.5 million in cash, cash equivalents, and short-term marketable securities as of March 31, 2020.